Top

Published in:

01-11-2015 | Original Article

Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results

Authors: Susanne Tewes, Katja Hueper, Dagmar Hartung, Florian Imkamp, Thomas R. W. Herrmann, Juergen Weidemann, Stefan Renckly, Markus A. Kuczyk, Frank Wacker, Inga Peters

Published in: World Journal of Urology | Issue 11/2015

Abstract

Purpose

To evaluate a novel system for MRI/TRUS fusion-guided biopsy for detection of prostate cancer (PCa) in patients with previous negative prostate biopsy and determine diagnostic accuracy when using the Prostate Imaging Reporting and Data System (PI-RADS) for multiparametric magnetic resonance imaging (mpMRI) as proposed by the European Society of Urogenital Radiology.

Methods

Thirty-nine men with clinical suspicion of PCa and history of previous prostate biopsy underwent mpMRI on a 3-T MRI. In total, 72 lesions were evaluated by the consensus of two radiologists. PI-RADS scores for each MRI sequence, the sum of the PI-RADS scores and the global PI-RADS were determined. MRI/TRUS fusion-guided targeted biopsy was performed using the BioJet™ software combined with a transrectal ultrasound system. Image fusion was based on rigid registration. PI-RADS scores of the dominant lesion were compared with histopathological results. Diagnostic accuracy was determined using receiver operating characteristic curve analysis.

Results

MRI/TRUS fusion-guided biopsy was reliable and successful for 71 out of 72 lesions. The global PI-RADS score of the dominant lesion was significantly higher in patients with PCa (4.0 ± 1.3) compared to patients with negative histopathology (2.6 ± 0.8; p = 0.0006). Using a global PI-RADS score cut-off ≥4, a sensitivity of 85 %, a specificity of 82 % and a negative predictive value of 92 % were achieved.

Conclusions

The described fusion system is dependable and efficient for targeted MRI/TRUS fusion-guided biopsy. mpMRI PI-RADS scores combined with a novel real-time MRI/TRUS fusion system facilitate sufficient diagnosis of PCa with high sensitivity and specificity.

Gosselaar C, Roobol MJ, van den Bergh RC, Wolters T, Schroder FH (2009) Digital rectal examination and the diagnosis of prostate cancer–a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam. Eur Urol 55(1):139–146. doi:10.1016/j.eururo.2008.03.079 CrossRefPubMed

Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC Jr, Group SDS (2007) Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 69(3):495–499. doi:10.1016/j.urology.2006.10.036 PubMedCentralCrossRefPubMed

Suardi N, Capitanio U, Chun FK, Graefen M, Perrotte P, Schlomm T, Haese A, Huland H, Erbersdobler A, Montorsi F, Karakiewicz PI (2008) Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 113(8):2068–2072. doi:10.1002/cncr.23827 CrossRefPubMed

Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ, Giannarini G, Kibel AS, Montironi R, Ploussard G, Roobol MJ, Scattoni V, Jones JS (2013) Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol 63(2):214–230. doi:10.1016/j.eururo.2012.09.033 CrossRefPubMed

Djavan BOB, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M (2001) Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166(5):1679–1683. doi:10.1016/S0022-5347(05)65652-2 CrossRefPubMed

Shariat SF, Roehrborn CG (2008) Using biopsy to detect prostate cancer. Rev Urol 10(4):262–280PubMedCentralPubMed

Roehrborn CG, Pickens GJ, Sanders JS (1996) Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology 47(3):347–352CrossRefPubMed

Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183(3):963–968. doi:10.1016/j.juro.2009.11.043 CrossRefPubMed

Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C, Emberton M (2009) Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 6(4):197–206. doi:10.1038/nrclinonc.2009.18 CrossRefPubMed

10.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, European Association of U (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71. doi:10.1016/j.eururo.2010.10.039 CrossRefPubMed

11.

Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H (2008) MR imaging of the prostate in clinical practice. MAGMA 21(6):379–392. doi:10.1007/s10334-008-0138-y CrossRefPubMed

12.

Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59(4):477–494. doi:10.1016/j.eururo.2010.12.009 CrossRefPubMed

13.

Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin P, Kirkham AP, Padhani AR, Persad R, Puech P, Punwani S, Sohaib A, Tombal B, Villers A, Emberton M (2013) Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging 37(1):48–58. doi:10.1002/jmri.23689 CrossRefPubMed

14.

Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ, European Society of Urogenital R (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757. doi:10.1007/s00330-011-2377-y PubMedCentralCrossRefPubMed

15.

Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, Hoang AN, Walton-Diaz A, Shuch B, Weintraub M, Kruecker J, Amalou H, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA (2013) Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 64(5):713–719. doi:10.1016/j.eururo.2013.05.059 CrossRefPubMed

16.

Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, Taneja SS, Emberton M (2013) Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 63(1):125–140. doi:10.1016/j.eururo.2012.06.004 CrossRefPubMed

17.

Roethke MC, Kuru TH, Schultze S, Tichy D, Kopp-Schneider A, Fenchel M, Schlemmer HP, Hadaschik BA (2014) Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol 24(2):344–352. doi:10.1007/s00330-013-3017-5 CrossRefPubMed

18.

Kuru TH, Saeb-Parsy K, Cantiani A, Frey J, Lombardo R, Serrao E, Gaziev G, Koo B, Roethke M, Gnanapragasam V, Warren A, Doble A, Hadaschik B, Kastner C (2014) Evolution of repeat prostate biopsy strategies incorporating transperineal and MRI-TRUS fusion techniques. World J Urol 32(4):945–950. doi:10.1007/s00345-014-1334-1 CrossRefPubMed

19.

Marks L, Young S, Natarajan S (2013) MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol 23(1):43–50. doi:10.1097/MOU.0b013e32835ad3ee PubMedCentralCrossRefPubMed

20.

D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRefPubMed

21.

Shoji S, Hiraiwa S, Endo J, Hashida K, Tomonaga T, Nakano M, Sugiyama T, Tajiri T, Terachi T, Uchida T (2014) Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience. Int J Urol: Off J Jpn Urol Assoc. doi:10.1111/iju.12643

22.

Rothke M, Blondin D, Schlemmer HP, Franiel T (2013) PI-RADS classification: structured reporting for MRI of the prostate. Rofo 185(3):253–261. doi:10.1055/s-0032-1330270 CrossRefPubMed

23.

Schimmoller L, Quentin M, Arsov C, Hiester A, Buchbender C, Rabenalt R, Albers P, Antoch G, Blondin D (2014) MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. Eur Radiol 24(10):2582–2589. doi:10.1007/s00330-014-3276-9 CrossRefPubMed

24.

Ashley T (2005) Using predictive value, sensitivity and specificity to interpret laboratory tests: PSA for the diagnosis of prostate cancer. J Insur Med 37(4):261–263PubMed

25.

Bott SR, Young MP, Kellett MJ, Parkinson MC, Contributors to the UCLHTRPD (2002) Anterior prostate cancer: is it more difficult to diagnose? BJU Int 89(9):886–889CrossRefPubMed

26.

Chun FK, Herrmann TR (2014) Prostate imaging—the future is now: current concepts and future potentials. World J Urol 32(4):843–845. doi:10.1007/s00345-014-1354-x CrossRefPubMed

27.

Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, Claussen CD, Stenzl A, Schlemmer HP, Schilling D (2012) MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 30(2):213–218. doi:10.1007/s00345-011-0675-2 CrossRefPubMed

28.

Schimmoller L, Quentin M, Arsov C, Lanzman RS, Hiester A, Rabenalt R, Antoch G, Albers P, Blondin D (2013) Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. Eur Radiol 23(11):3185–3190. doi:10.1007/s00330-013-2922-y CrossRefPubMed

29.

de Rooij M, Crienen S, Witjes JA, Barentsz JO, Rovers MM, Grutters JP (2013) Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. Eur Urol. doi:10.1016/j.eururo.2013.12.012 PubMed

30.

Mowatt G, Scotland G, Boachie C, Cruickshank M, Ford JA, Fraser C, Kurban L, Lam TB, Padhani AR, Royle J, Scheenen TW, Tassie E (2013) The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. Health Technol Assess 17(20):1–281. doi:10.3310/hta17200 CrossRefPubMed

Title: Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results
Authors: Susanne Tewes
Katja Hueper
Dagmar Hartung
Florian Imkamp
Thomas R. W. Herrmann
Juergen Weidemann
Stefan Renckly
Markus A. Kuczyk
Frank Wacker
Inga Peters
Publication date: 01-11-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 11/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-015-1525-4

At a glance: The STEP trials

Springer Medicine

Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2015

Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients

The vacuum cleaner effect in minimally invasive percutaneous nephrolitholapaxy

Nomenclature in PCNL or The Tower Of Babel: a proposal for a uniform terminology

Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes

Functional outcomes of adjustable continence therapy (ACT™) balloons in women aged >80 years and suffering from stress urinary incontinence caused by intrinsic sphincter deficiency

The value of urodynamic tools to guide patient selection in sacral neuromodulation